Intracellular Th (ITCI) has had the highest return since January 1, 2025 by a US stock in the Pharmaceuticals Industry with a market cap of $10B+, returning 56.7%.
| ASSET | % RETURN |
|---|---|
Intracellular Th (ITCI) | 56.69% |
Royalty Pharma (RPRX) | 26.86% |
Novartis AG ADR (NVS) | 19.14% |
Takeda Pharmaceutical Co Ltd ADR (TAK) | 13.86% |
Eli Lilly and (LLY) | 13.51% |
GlaxoSmithKline PLC ADR (GSK) | 11.49% |
Sanofi ADR (SNY) | 8.28% |
Johnson & Johnson (JNJ) | 7.29% |
AstraZeneca PLC ADR (AZN) | 6.87% |
Zoetis (ZTS) | -6.31% |
Dr Reddy’s Laboratories Ltd ADR (RDY) | -12.39% |
Pfizer (PFE) | -12.9% |
Bristol-Myers Squibb (BMY) | -14.01% |
Merck (MRK) | -16.78% |
Novo Nordisk A-S (NVO) | -28.24% |
Teva Pharma Industries Ltd ADR (TEVA) | -32.5% |
